MeSH term
Frequency | Condition_Probility | Humans | 326 | 0.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Amino Acid Sequence | 7 | 0.0 |
Animals | 42 | 0.0 |
Cell Line | 5 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Gene Expression Regulation, Developmental | 8 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Mutation | 5 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 83 | 0.0 |
Signal Transduction | 9 | 0.0 |
Transforming Growth Factor beta/genetics/metabolism | 2 | 5.0 |
Aged | 152 | 0.0 |
*Apoptosis | 2 | 0.0 |
Cell Differentiation | 5 | 0.0 |
Female | 225 | 0.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Male | 175 | 0.0 |
Middle Aged | 182 | 0.0 |
Neoplasm Staging | 63 | 2.0 |
Prognosis | 68 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 2 | 0.0 |
Retrospective Studies | 38 | 1.0 |
Survival Rate | 36 | 1.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Chick Embryo | 3 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Transforming Growth Factor beta/*genetics | 2 | 2.0 |
Disease Progression | 4 | 0.0 |
Neoplasm Invasiveness | 16 | 1.0 |
Neoplasm Metastasis | 10 | 0.0 |
Phenotype | 4 | 0.0 |
Receptors, Estrogen/analysis | 6 | 1.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Child, Preschool | 9 | 0.0 |
*Epidermal Growth Factor | 4 | 8.0 |
*Homeodomain Proteins | 4 | 1.0 |
*Membrane Glycoproteins | 5 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 46 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
*Transcription Factors | 6 | 0.0 |
*Zebrafish Proteins | 5 | 2.0 |
Cells, Cultured | 3 | 0.0 |
Glycosylation | 2 | 0.0 |
*Proteins | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Transforming Growth Factor beta/genetics/*metabolism | 4 | 10.0 |
Aged, 80 and over | 58 | 0.0 |
Disease-Free Survival | 19 | 2.0 |
Treatment Failure | 2 | 0.0 |
Colorectal Neoplasms/*pathology | 3 | 5.0 |
Lymph Nodes/pathology | 14 | 4.0 |
Lymphatic Metastasis/pathology | 4 | 5.0 |
Neoplasm Staging/*methods | 5 | 13.0 |
Sensitivity and Specificity | 16 | 0.0 |
Adult | 140 | 0.0 |
Blotting, Western | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Immunohistochemistry | 27 | 0.0 |
*Lymphatic Metastasis | 8 | 21.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Comparative Study | 37 | 0.0 |
English Abstract | 42 | 0.0 |
Follow-Up Studies | 35 | 0.0 |
Iodine Radioisotopes/therapeutic use | 2 | 5.0 |
*Lymph Node Excision | 13 | 72.0 |
Neoplasm Recurrence, Local | 9 | 2.0 |
Patient Selection | 2 | 1.0 |
Risk Factors | 12 | 0.0 |
Survival Analysis | 28 | 1.0 |
Thyroidectomy | 3 | 2.0 |
Time Factors | 29 | 0.0 |
Cohort Studies | 4 | 0.0 |
Colectomy | 2 | 7.0 |
Dyes/diagnostic use | 2 | 2.0 |
False Negative Reactions | 5 | 3.0 |
Feasibility Studies | 2 | 0.0 |
Forecasting | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
*Sentinel Lymph Node Biopsy | 7 | 35.0 |
Activin Receptors, Type I/metabolism | 3 | 16.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Xenopus | 5 | 0.0 |
*Xenopus Proteins | 9 | 2.0 |
Carcinoma, Squamous Cell/*pathology | 3 | 3.0 |
Keratin/analysis | 2 | 0.0 |
Base Sequence | 7 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Mice | 17 | 0.0 |
Endoderm/metabolism | 2 | 11.0 |
Gene Targeting | 3 | 0.0 |
Pregnancy | 2 | 0.0 |
Lymphatic Metastasis | 63 | 6.0 |
Sentinel Lymph Node Biopsy | 3 | 23.0 |
Analysis of Variance | 6 | 0.0 |
Pelvis | 7 | 26.0 |
Proportional Hazards Models | 14 | 2.0 |
Prospective Studies | 22 | 0.0 |
Treatment Outcome | 23 | 0.0 |
Mastectomy | 5 | 7.0 |
Chi-Square Distribution | 7 | 0.0 |
Lymph Nodes/*pathology | 16 | 16.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Models, Theoretical | 2 | 1.0 |
*Tomography, X-Ray Computed | 4 | 4.0 |
Palpation | 2 | 25.0 |
False Positive Reactions | 2 | 0.0 |
Neck | 5 | 8.0 |
Neck Dissection | 3 | 37.0 |
Predictive Value of Tests | 10 | 0.0 |
Statistics | 2 | 0.0 |
Bone Morphogenetic Proteins/metabolism | 3 | 5.0 |
*Gene Expression Regulation, Developmental | 5 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Mutagenesis | 3 | 0.0 |
Incidence | 3 | 0.0 |
Axilla | 14 | 22.0 |
Reproducibility of Results | 2 | 0.0 |
Technetium/*diagnostic use | 2 | 8.0 |
Technetium Tc 99m Aggregated Albumin/*diagnostic use | 3 | 25.0 |
Breast Neoplasms/*pathology | 10 | 4.0 |
Carcinoma/*pathology | 4 | 7.0 |
Electrophysiology | 29 | 6.0 |
Sentinel Lymph Node Biopsy/*methods | 2 | 25.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Lymph Node Excision | 13 | 18.0 |
Lymphatic Metastasis/diagnosis | 2 | 11.0 |
Ovarian Neoplasms/*pathology/surgery | 2 | 100.0 |
Esophagectomy | 3 | 21.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Homeodomain Proteins/metabolism | 2 | 2.0 |
Mesoderm/cytology/physiology | 2 | 20.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
Zebrafish | 2 | 1.0 |
Adolescent | 37 | 0.0 |
Heart/embryology | 2 | 3.0 |
*Intercellular Signaling Peptides and Proteins | 5 | 0.0 |
Models, Biological | 2 | 0.0 |
Morphogenesis | 2 | 0.0 |
Gene Expression | 5 | 0.0 |
Chromosome Aberrations/genetics | 2 | 1.0 |
Gene Amplification/genetics | 2 | 3.0 |
G(M1) Ganglioside/immunology | 2 | 20.0 |
Molecular Weight | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Receptor, erbB-2/*metabolism | 3 | 1.0 |
Biopsy | 5 | 0.0 |
Multivariate Analysis | 16 | 1.0 |
Body Patterning/genetics/*physiology | 2 | 50.0 |
Ectoderm/physiology | 3 | 21.0 |
Genetic Markers | 2 | 0.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Catheter Ablation/*methods | 4 | 80.0 |
Electrocardiography | 37 | 11.0 |
Tachycardia, Atrioventricular Nodal Reentry/*surgery | 2 | 100.0 |
Cell Line, Tumor | 3 | 0.0 |
Child | 16 | 0.0 |
Electric Stimulation | 2 | 0.0 |
Tachycardia, Paroxysmal/*physiopathology | 2 | 66.0 |
*Nuclear Proteins | 4 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Atrioventricular Node/*physiopathology | 23 | 92.0 |
*Catheter Ablation | 10 | 23.0 |
Age Factors | 11 | 0.0 |
Mesoderm/metabolism | 3 | 3.0 |
Adenocarcinoma/*pathology | 2 | 2.0 |
Neoplasm Recurrence, Local/*pathology | 2 | 15.0 |
Recurrence | 9 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 6 | 0.0 |
Lymphatic Metastasis/*diagnosis | 3 | 15.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
*Models, Biological | 2 | 1.0 |
Probability | 2 | 0.0 |
Algorithms | 3 | 0.0 |
Breast Neoplasms/*pathology/radiotherapy/surgery | 2 | 100.0 |
Intraoperative Care | 2 | 8.0 |
Mastectomy, Segmental | 3 | 17.0 |
Radiotherapy, Adjuvant | 8 | 9.0 |
Chemotherapy, Adjuvant | 10 | 4.0 |
Combined Modality Therapy | 25 | 2.0 |
*Pancreatectomy | 2 | 22.0 |
Antigens, CD/analysis | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Immunophenotyping | 2 | 0.0 |
Diagnosis, Differential | 4 | 0.0 |
Inflammation | 2 | 0.0 |
Hysterectomy | 4 | 5.0 |
Regression Analysis | 4 | 0.0 |
Keratin/*analysis | 2 | 6.0 |
Protein p53/analysis | 2 | 0.0 |
Electrocardiography, Ambulatory | 4 | 13.0 |
Heart Rate | 8 | 3.0 |
Cyclophosphamide/administration & dosage | 4 | 1.0 |
*Nucleoside-Diphosphate Kinase | 2 | 3.0 |
Pilot Projects | 2 | 0.0 |
Alleles | 3 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Dextrocardia/embryology/genetics | 2 | 66.0 |
Embryonic and Fetal Development/*genetics | 2 | 2.0 |
Fetal Heart/abnormalities | 2 | 100.0 |
Genotype | 2 | 0.0 |
Growth Substances/*physiology | 2 | 1.0 |
Heart Defects, Congenital/embryology/genetics | 2 | 33.0 |
Homeodomain Proteins/genetics/physiology | 2 | 10.0 |
Mice, Knockout | 4 | 0.0 |
Morphogenesis/*genetics | 2 | 28.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Spleen/abnormalities | 2 | 28.0 |
Syndrome | 4 | 0.0 |
Transcription Factors/genetics/physiology | 2 | 3.0 |
Transforming Growth Factor beta/deficiency/genetics/physiology | 2 | 100.0 |
Transposition of Great Vessels/embryology/genetics | 2 | 100.0 |
Viscera/abnormalities | 2 | 66.0 |
Tachycardia, Atrioventricular Nodal Reentry/physiopathology | 2 | 66.0 |
Transforming Growth Factor beta/metabolism | 3 | 1.0 |
Atrioventricular Node/physiopathology/*surgery | 2 | 100.0 |
Tachycardia, Atrioventricular Nodal Reentry/physiopathology/*surgery | 6 | 100.0 |
Heart Atria/physiopathology | 5 | 62.0 |
Mice, Transgenic | 2 | 0.0 |
Sinoatrial Node/*physiopathology | 8 | 57.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
*Cardiac Pacing, Artificial | 3 | 33.0 |
Evaluation Studies | 5 | 0.0 |
Neoplasm Recurrence, Local/epidemiology | 3 | 15.0 |
Flow Cytometry | 3 | 0.0 |
*Ploidies | 3 | 4.0 |
Neoplasm, Residual | 2 | 2.0 |
Radiotherapy, High-Energy | 2 | 16.0 |
Chronic Disease | 4 | 0.0 |
Actuarial Analysis | 4 | 5.0 |
*Ampulla of Vater | 2 | 18.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Sick Sinus Syndrome/*physiopathology | 2 | 50.0 |
Breast Neoplasms/*pathology/surgery | 3 | 18.0 |
Protein p53/metabolism | 2 | 0.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Adenocarcinoma/*surgery | 2 | 33.0 |
Lymph Node Excision/*methods | 5 | 50.0 |
Anti-Arrhythmia Agents/administration & dosage/*therapeutic use | 2 | 100.0 |
Arrhythmia/*drug therapy | 3 | 27.0 |
Wolff-Parkinson-White Syndrome/drug therapy | 2 | 100.0 |
Anti-Arrhythmia Agents/therapeutic use | 2 | 15.0 |
Atrioventricular Node/*surgery | 2 | 100.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Electrocardiography/drug effects | 2 | 6.0 |
Catheter Ablation/*adverse effects | 2 | 20.0 |
Phenylephrine/pharmacology | 2 | 5.0 |
Postoperative Period | 3 | 0.0 |
Vagus Nerve/drug effects/*physiopathology | 2 | 100.0 |
Inguinal Canal/surgery | 2 | 100.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Infusions, Intravenous | 3 | 0.0 |
Atrial Fibrillation/physiopathology/*surgery | 2 | 100.0 |
Cardiac Pacing, Artificial | 25 | 55.0 |
Case-Control Studies | 2 | 0.0 |
Atropine/diagnostic use | 3 | 42.0 |
Heart Catheterization | 5 | 7.0 |
Heart Rate/drug effects | 5 | 2.0 |
Biopsy, Needle | 3 | 0.0 |
Breast Neoplasms/chemistry/*pathology/surgery | 2 | 28.0 |
Breast Neoplasms/*metabolism/pathology | 4 | 2.0 |
Protein p53/*metabolism | 2 | 0.0 |
Echocardiography | 2 | 0.0 |
Postoperative Complications | 3 | 2.0 |
Pacemaker, Artificial | 4 | 33.0 |
*Atrial Function | 2 | 25.0 |
Tachycardia, Atrioventricular Nodal Reentry/*physiopathology | 4 | 66.0 |
Wolff-Parkinson-White Syndrome/*physiopathology | 4 | 100.0 |
Central Nervous System/*ultrastructure | 2 | 66.0 |
Microscopy, Electron | 2 | 0.0 |
Myelin Sheath/*ultrastructure | 2 | 33.0 |
Rats | 3 | 0.0 |
Carcinoma, Squamous Cell/*immunology | 2 | 7.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Infant | 6 | 0.0 |
Radiotherapy Dosage | 5 | 3.0 |
Remission Induction | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Preoperative Care | 4 | 2.0 |
Cervix Neoplasms/*pathology | 2 | 9.0 |
Japan | 2 | 0.0 |
Atrioventricular Node/*drug effects | 4 | 100.0 |
*Pacemaker, Artificial | 2 | 12.0 |
Lymphatic Metastasis/*pathology | 3 | 8.0 |
Postoperative Care | 2 | 2.0 |
Databases, Factual | 2 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Arrhythmia/*physiopathology | 4 | 57.0 |
Cardiac Complexes, Premature/physiopathology | 2 | 100.0 |
*Electrocardiography | 9 | 15.0 |
Brachytherapy | 2 | 20.0 |
Gamma Cameras | 2 | 40.0 |
Lymphatic Metastasis/radionuclide imaging | 2 | 33.0 |
Technetium Compounds/diagnostic use | 2 | 66.0 |
Prostate-Specific Antigen/*blood | 2 | 2.0 |
Postmenopause | 2 | 1.0 |
*Lymphography | 2 | 100.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Proto-Oncogene Proteins/*analysis | 4 | 2.0 |
*Proto-Oncogenes | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*analysis | 3 | 0.0 |
Receptor, erbB-2 | 5 | 3.0 |
Action Potentials | 2 | 3.0 |
Rabbits | 3 | 0.0 |
Cell Division | 2 | 0.0 |
Nuclear Proteins/*analysis | 2 | 1.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Serum Albumin/diagnostic use | 2 | 66.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Injections, Intravenous | 4 | 0.0 |
Radiopharmaceuticals/*diagnostic use | 2 | 4.0 |
Diltiazem/*pharmacology | 3 | 25.0 |
Heart/physiopathology | 2 | 5.0 |
Kinetics | 2 | 0.0 |
Refractory Period, Neurologic/drug effects | 3 | 75.0 |
Sinoatrial Node/physiology | 4 | 80.0 |
Tachycardia/physiopathology | 5 | 62.0 |
Methods | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
*Brachytherapy | 2 | 22.0 |
Carcinoma, Squamous Cell/mortality/radiotherapy/*surgery | 2 | 66.0 |
Palliative Care | 2 | 4.0 |
Bradycardia/physiopathology | 2 | 50.0 |
Heart Conduction System/physiopathology | 2 | 11.0 |
Administration, Oral | 2 | 0.0 |
Heart Conduction System/drug effects | 2 | 40.0 |
Tachycardia, Supraventricular/*drug therapy | 2 | 100.0 |
Axilla/surgery | 2 | 66.0 |
Breast/pathology | 3 | 10.0 |
Tachycardia, Supraventricular/*physiopathology | 3 | 100.0 |
Atrioventricular Node/drug effects/*physiopathology | 2 | 100.0 |
Heart Conduction System/*physiopathology | 27 | 72.0 |
Transforming Growth Factor beta/*metabolism | 3 | 1.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
*Electrophysiology | 3 | 37.0 |
Sinoatrial Node/drug effects | 3 | 100.0 |
Gastrectomy | 2 | 3.0 |
SEER Program | 2 | 8.0 |
Heart Conduction System/*surgery | 2 | 66.0 |
Iodine Radioisotopes/*diagnostic use | 2 | 3.0 |
Heart Block/physiopathology | 4 | 80.0 |
Lymph Nodes/*pathology/surgery | 2 | 50.0 |
Anti-Arrhythmia Agents/*therapeutic use | 2 | 22.0 |
Atrial Fibrillation/physiopathology | 3 | 75.0 |
Bundle of His/*physiopathology | 3 | 60.0 |
Heart Block/drug therapy | 3 | 100.0 |
Heart Conduction System/*drug effects | 4 | 44.0 |
Sinoatrial Node/*drug effects | 2 | 66.0 |
Mice, Mutant Strains | 2 | 0.0 |
Tachycardia, Paroxysmal/complications/*physiopathology | 2 | 100.0 |
Atrioventricular Node/drug effects | 3 | 100.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Coronary Disease/physiopathology | 3 | 18.0 |
Infusions, Parenteral | 2 | 1.0 |
Atrioventricular Node/physiopathology | 2 | 50.0 |
Sinoatrial Node/physiopathology | 2 | 100.0 |
Heart Ventricles/physiopathology | 3 | 7.0 |
Heart Block/*physiopathology | 2 | 50.0 |
Sick Sinus Syndrome/*drug therapy/physiopathology | 2 | 100.0 |
Sinoatrial Node/*drug effects/physiopathology | 3 | 100.0 |
Benzazepines/*pharmacology | 3 | 20.0 |
Bundle of His/physiopathology | 6 | 75.0 |
Purkinje Fibers/physiopathology | 3 | 75.0 |
Tachycardia, Paroxysmal/physiopathology | 3 | 100.0 |
Transforming Growth Factor beta/*physiology | 2 | 1.0 |
Tachycardia/*physiopathology | 3 | 50.0 |
Atropine/pharmacology | 2 | 5.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Heart Diseases/physiopathology | 2 | 50.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Heart Atria/*physiopathology | 2 | 100.0 |
